Neutralizing antibody appears to be an important component of the protective immune response against human immunodeficiency virus type 1 (HIV-1) infection (1, (4) (5) (6) . Sera from many HIV-1-infected individuals are able to neutralize a broad spectrum of virus isolates, indicating the presence of conserved neutralization epitopes (28, 37) . The induction of antibodies with broad neutralizing capacity is a primary goal of vaccine development strategies. Several reports have suggested that HIV-1 neutralizing activity is associated primarily with two regions of the gp120 envelope glycoprotein: the third hypervariable loop (V3) (8, 10, 29) and the CD4 binding site (CD4 b.s.) (11, 34) . Generally, antibodies specific for V3 arise early after HIV infection and exhibit the ability to neutralize a limited number of HIV-1 isolates. However, a limited number of V3 monoclonal antibodies (MAbs) recognize conserved features of the loop and subsequently exhibit a broader neutralization profile (7, 10, 24) . Later in the course of viral infection, antibodies capable of neutralizing a wider range of HIV-1 isolates are detectable (20, 28, 37) . The appearance of such crossneutralizing activity coincides with the detection of antibodies capable of blocking gp120-soluble CD4 (sCD4) interaction (9, 11, 18, 34) . A number of neutralizing MAbs derived both from infected individuals (9, 12, 26, 30, 36) and from recombinant gp120-immunized rats (3) which block gp120-sCD4 binding have been antibodies may play an important role in the cross-neutralizing response (21) .
The selection and characterization of neutralization-resistant escape mutants is one strategy for the identification of amino acid residues critical for the binding of neutralizing antibodies. We have selected escape variants which are resistant to both V3 MAbs and sCD4 (13, 15) . To define the epitopes responsible for inducing cross-neutralizing antibodies in human sera further, we selected an escape variant that could replicate in the presence of a neutralizing human serum. Characterization of the neutralization sensitivity of the escape variant with a panel of MAbs mapping to the second variable loop (V2), V3, and the CD4 b.s. demonstrated that the variant was resistant to a number of MAbs mapping to the CD4 b.s., suggesting that antibodies specific for the CD4 b.s. in human sera are capable of crossneutralizing a nonhomologous HIV-1 isolate (HXB2) and may be sufficient to select for neutralization-resistant escape mutants.
MATERIALS AND METHODS
Virus propagation and neutralization assays. (i) Transfection of H9 cells and viral stock production. H9 (17) . The lowest concentration of antibody or sCD4 resulting either in a complete blocking of syncytium formation or in a >90% reduction in p24 antigen production was defined as the reciprocal neutralization titer.
(iii) Comparative neutralization of variant and wt virus by human sera. Human serum neutralization titers were obtained for both variant and wild-type (wt) viruses. The differences in the titers were compared by using a two-tail nonparametric test (Wilcoxon's rank sum) (see Fig. 7 ).
MAbs and human sera. The following antibodies were used for neutralization studies and/or envelope binding studies: rat MAbs 10/54, 10/36e, and 11/85b, specific for amino acids 311 to 321 of the HXB10 V3 loop (14) Antibody and sCD4 binding to detergent-solubilized viral gp 120. Virus-containing supernatants were inactivated with 1% Nonidet P-40 (NP-40), which does not irreversibly denature gpl20/160 (23) . The concentrations of gpl20 present in the preparations were determined by a twin-site enzyme-linked immunosorbent assay (ELISA) as previously described (22, 23), using recombinant gpl20 (rgpl2O; BH10 clone), expressed in and purified from CHO cells, as a reference standard. Briefly, detergent-solubilized gpl20 from wt, variant, and 375 S/N (see Results for definition) site-directed mutant viral stocks was allowed to bind to the solid phase via the capture antibody D7324 (anti-C terminus; Aalto-Bioreagents, Dublin, Ireland) at an input concentration of 50 ng/ml. The abilities of MAbs and sCD4 to bind to the captured gpl20 were assessed by using methods previously published (13, 19 Cassette vector construction and site-directed mutagenesis. The HXB2 insert of plasmid pHXB2gpt was transferred into a vector lacking XbaI sites by ligation into the NheI site of a pSPTBM20 vector (Boehringer Mannheim), from which the polylinker had previously been excised by double digestion with SmaI and EcoRV and self-ligation. A derivative, MCS, was constructed by introducing a silent site-directed mutation in the gpl60 gene to generate an XbaI site and two nonsilent changes in the nonfunctional vpu gene to generate a NotI site. Virus recovered upon transfection of the modified plasmid was able to infect H9 cells with the same the NheI end and self-ligation. This digestion excised a 295-bp piece of the envelope gene including the V4, C4, and V5 domains (see Fig. 3 ), and the plasmid was shown to be noninfectious (data not shown).
Generation and cloning of wild-type and variant gpl20 molecules. Single molecules of gpl20 were amplified by a limit dilution method (31) using nested primers specific for the vpu region (sense) and for the gp4l molecule (antisense). Site-directed mutation and cloning of gp120 molecules. Site-directed mutagenesis of the HXB2 envelope was performed by a modification of the method of Wolfs et al. (38) , using PFU polymerase in place of Taq polymerase. Two 20-pl PCR reactions were set up as described above, with 25 ng of pHXB2gpt as the template, using either the 3' antisense XbaI primer and a sense primer encoding the desired 375 mutation or the 5' sense NotI inner primer and a second, antisense, 375 primer. The use of this relatively large amount of template DNA allowed us to reduce the number of cycles performed in the PCR and hence the frequency of polymerase-introduced error; the PCR was run for 10 cycles, using the temperature profile described above for the second round. The PCR products were gel purified by a Gene-Clean procedure, and the two products were pooled into a 100-,ul PCR mix containing the 5' sense Notl inner primer and the 3'
antisense XbaI primer; this mixture was reamplified for a further 10 cycles, using the same temperature profile as before. The final, full-length product was separated from the two shorter products on a 1.5% agarose gel, purified, cloned, and screened as described above. The presence of the desired change was verified by sequencing.
RESULTS
Selection procedure. Experiments were designed to monitor the kinetics of the appearance of HIV-1 escape mutants propagated in the presence of a HIV-1-positive human serum. The serum chosen, QC5 (16) , neutralized HXB2 at a serum dilution of 1/640 and contained antibodies capable of blocking the gpl2O-sCD4 interaction (data not shown). Virus obtained by transfection of the HIV-1 molecular clone HXB2 into C8166 cells was allowed to infect the H9 cell line at multiplicities of infection of 0.1 and 0.01 for 2 h at 37°C. After viral adsorption, unbound virus was removed by washing and the cells were cultured in the presence of either a seronegative human serum (AB') or serum QC5 at final dilutions of 1/40, 1/80, 1/160, and 1/320. Cultures were fed biweekly with the human sera and were monitored for both cytopathic effect and p24 antigen production.
After 2 weeks, virus was recovered as cell-free supematant from the cultures containing the lowest serum dilutions (1/160 and 1/320). After 4 weeks of propagation, viral antigen (p24) was detected in the culture containing QC5 at a 1/80 dilution. Over a 7-week period, no evidence for viral replication was observed in the highest concentration of selecting serum (1/40). The virus-containing supernatants were tested for sensitivity to neutralization by the selecting serum. Virus rescued from the cultures containing QC5 at a 1/80 dilution was partially resistant to neutralization by QC5 (Table 1) . However, virus obtained in the presence of the two lowest concentrations of QC5 was not resistant to neutralization by the selecting serum (data not shown).
This partially resistant virus was tested for its sensitivity to neutralization by sCD4 and a number of rat gpl20 MAbs: 39.13g, binding to a discontinuous epitope overlapping with that of CD4 and capable of blocking the gpl2O-sCD4 interaction (3, 19); 10/54, 10/36e, 11/85b, and 41.1, binding to epitopes in the V3 loop (14) ; and 10/76b, binding to a linear epitope in the V2 loop (17a). The variant was resistant to neutralization both by MAb 39.13g and by sCD4 (Table 1) . However, the variant was as susceptible as the parental virus to neutralization by all of the V2 and V3 MAbs (Table   1) .
MAb recognition of variant gp120. We measured the ability of sCD4 and MAbs 39.13g and 41.1 to bind to nonionic detergent (NP-40)-solubilized wt and variant viral gpl20 (at an input concentration of 50 ng/ml). The V3 MAb 41.1 bound to the variant and wt gpl20 with comparable affinities (Fig.  IA) . In contrast, MAb 39.13 g showed a reduced binding affinity (10.6-fold) for the variant gpl20 (Fig. 1B) , in agreement with the reduced ability of the MAb to neutralize the variant. However, sCD4 bound to the variant gpl20 with an affinity comparable to that of the wt (Fig. 1C) , which was unexpected given the reduced ability of sCD4 to neutralize the variant (Table 1) . We have previously reported differences in the abilities of both MAbs (14) and sCD4 (22) (Fig. 2B) . A saturating concentration of sCD4 (10 ,ug/ml) bound equivalently to wt-infected and variant-infected cells, with mean fluorescence intensities of 170 and 176, respectively (Fig. 2C) . However, concentrations of sCD4 resulting in half-maximal binding (1.0 ,ug/ml) demonstrated a twofold reduction in binding to variant-infected cells compared with wt-infected cells, suggesting that the native variant envelope had a reduced binding affinity for sCD4 (Fig.2C) . V3 MAb 41.1 bound to wt-infected and variant-infected cells with similar affinities, suggesting that the level of gpl20 cell surface expression was comparable in the infected cultures ( Fig. 2A) . The We have previously identified gp120 residues 113, 117, 256, 257, 262, 368, 370, and 421 as being involved in the binding of MAb 39.13g (19) . These regions overlap with those reported to be important for sCD4 binding (25) . We therefore sequenced the gp120 of both the variant and wt viruses and identified a single amino acid substitution at codon 375 (AGT->AAT, Ser--Asn; designated 375 S/N). To confirm that the gpl20 mutation at 375 is responsible for the resistance of the variant to 39.13g neutralization, we cloned both the wt and variant gpl20 genes into a viable HIV-1 cassette vector, pHXB2-MCS (Fig. 3) . In addition, we generated a synthetic mutation at codon 375 by site-directed mutagenesis and also cloned this mutated gpl20 into pHXB2-MCS. The viral stocks recovered from transfection with several clones, named HXB2-wt, HXB2-var, and HXB2-375 S/N, respectively, were tested both for their sensitivities to neutralization by the original selecting serum QC5 and a range of neutralizing MAbs and for their abilities to bind MAbs. HXB2-var (clone 23) and HXB2-375 S/N (clone 9) were both resistant to neutralization by QC5 and 39.13g but remained sensitive to neutralization by MAbs specific for the V2 and V3 domains ( Table 2 ), confirming that the mutation at residue 375 is responsible for the neutralization-resistant phenotype. Additional clones of HXB2-var and HXB2-375 S/N demonstrated similar neutralization profiles (data not shown).
Neutralization and MAb binding to the 375 S/N site-directed mutant. There are a number of neutralizing human MAbs which block gpl2O-sCD4 binding and which have similar binding properties to a panel of site-directed gpl20 mutants as 39.13g (19, 30, 33, 35) . All of the human MAbs tested were able to cross-compete with 39.13g for gpl20 binding (Fig. 4) (12), and 2.1h (35) but were resistant to neutralization by three additional MAbs, 1.5e (9), G13 (30) , and 448 (12) ( Table 2 ). MAbs 1.5e and G13 showed reduced binding indices for both the cloned variant and the 375 S/N site-directed mutant viral gp120, both by ELISA (Fig. 5) and by cell surface fluorescence-activated cell-sorting (FACS) analysis (data not shown), in good agreement with the observed resistance to neutralization. However, MAb 448, which demonstrated a reduced ability a All antibodies and sCD4 were tested at a final concentration of 10.0 pLg/ml with the exceptions of 559 (0.86 ,ug/ml), 728 (2.20 ,ug/ml), 654 (5.30 ,ug/ml), and 729 (1.94 pg/ml), which were tested at the highest concentrations feasible (in parentheses). The selecting serum QC5 was tested at a final dilution of 1/100. to neutralize both the variant and 375 S/N mutant viruses (Table 2) , bound to detergent-solubilized gp120/160 with binding indices of 0.81 and 0.82, respectively. Furthermore, no detectable difference in the ability of MAb 448 to bind to the surface of wt-or variant-infected H9 cells was observed by FACS staining (data not shown). The remaining six human MAbs and three control MAbs, mapping to V2, V3, and C4, bound to the variant and 375 S/N site-directed mutant antigens with binding indices ranging from 0.8 to 1.20 ( Fig. 5) .
Since MAbs 39.13g, 1.5e, and G13 still bind to HXB2-375 S/N, though with reduced binding indices, we investigated the mechanism of neutralization resistance. Since all of these MAbs block in vitro the gpl20-sCD4 interaction, they presumably neutralize by preventing virion attachment to CD4. We therefore tested the ability of a number of CD4 b.s. MAbs, together with control MAbs specific for the V2, V3, and C4 regions of gpl20, to block sCD4 binding to NP-40-solubilized HXB2-wt, HXB2-var, and HXB2-375 S/N viral gpl20 by ELISA. MAbs 39.13g, 1.5e, and G13 (5 ,ug/ml) blocked sCD4 binding to HXB2-wt gpl20 by 82, 83, and 79%, to HXB2-375 S/N mutant by 27, 29, and 20, and to HXB2-var by 24, 22, and 26%, respectively (Fig. 6 ). Since the gpl20-sCD4 binding assay was performed with NP-40-solubilized viral g120, it is not surprising that MAb 448 inhibited sCD4 binding to wt and variant gpl20 equivalently (Fig. 6 ).
Since the 375 S/N mutation was originally selected for by an HIV-1-positive human serum, we investigated the sensitivity of the variant to neutralization by a panel of sera from HIV-1-infected individuals classified in CDC stages II and III (Fig. 7) . Eleven of 21 sera showed a reduced neutralization titer for the variant, with a median neutralization titer of 1/20, compared with 1/40 for HXB2-wt (P = 0.0092, twotailed Wilcoxon rank test).
DISCUSSION
We have selected an HIV-1 variant which can replicate in the presence of a neutralizing human serum (Table 1) .
Sequencing of the gpl20 genes from both the variant and the wt virus identified a single amino acid change in the C3 region of gpl20, at residue 375 from Ser to Asn. Characterization of this mutation, both as a cloned variant gpl20 (HXB2-var) and as a site-directed mutant (HXB2-375 S/N), demonstrated that the mutation conferred resistance to neutralization by MAbs 39.13g (3), 1.5e (9), G13 (30) , and 448 (12), binding to epitopes overlapping the CD4 b.s., and by sCD4 (Table 2 We have previously reported a difference in the ability of sCD4 to bind to soluble gpl20 and native intact virion gpl20 (22) , suggesting that the tertiary and/or quarternary structure of native oligomeric gpl20/41 influences the binding affinity of sCD4.
MAbs 39.13g, 1.5e, and G13 were less efficient at blocking sCD4 binding to solubilized HXB2-var and HXB2-375 S/N viral gpl20 than to HXB2-wt gpl20 (Fig. 6) , suggesting that the efficiency of neutralization by CD4 b.s. antibodies may be governed by the affinity of the antibody for the envelope glycoprotein. By using a panel of site-directed gpl20 mutants, the epitopes recognized by the CD4 b.s. MAbs, with the exception of 728 and 654, have been mapped (19, 30, 33, 35) (25) . Thus, a number of amino acid residue changes significantly affect MAb binding without affecting sCD4 recognition, suggesting that viral escape from antibody neutralization may occur without affecting the ability of the virus to bind to its receptor (19) . However, the 375 S/N variant was also resistant to neutralization by sCD4 (Tables 1 and 2 ). sCD4 demonstrated a reduced binding affinity for native envelope but not for detergent-solubilized gpl20 ( Fig. 1 and 2 ). Olshevsky and colleagues (25) reported that mutation of residues 368 and 370 abrogated sCD4 binding in the presence or absence of nonionic detergents; however, residue 375 was not studied by these authors.
Reitz and colleagues (27) , and G13) were tested for the ability to inhibit sCD4 (1.0 1Lg/ml) binding to NP-40-solubilized gpl20/160 (50 ng/ml) from HXB2-wt, HXB2-var, and HXB2-375 S/N viral stocks.
reduction in the affinity of mutant 582 A/T for the MAbs or of mutant 375 S/N for MLAb 448, not measurable by current assays, may be sufficient to account for the differential neutralization observed (32) .
The 375 S/N mutant replicates in CD4+ cells as efficiently as the wt does, as assessed by measuring the infectivity-toparticle ratio (TCID50 virion p24) (data not shown) (17) . This finding is in agreement with the ability of sCD4 and sCD4-IgG neutralization-resistant variants to replicate as well as the neutralization-sensitive parental virus does (12a, 13) . This observation is consistent with reports that replicationcompetent viruses can exhibit a wide range of CD4-binding affinities and may be explained by the greater cooperativity
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. of envelope-receptor interactions during virus-cell or cellcell fusion compared with the interaction of soluble CD4 and gp120 (32) .
The ability of a polyclonal serum to select for a mutation in C3 which affects the sensitivity to neutralization both by sCD4 and CD4 b.s. MAbs confirms that antibodies binding to the CD4 b.s. contribute to the group-specific neutralization response (21, 32) . However, the 375 S/N mutant was only partially resistant to 11 of 21 human sera tested (Fig. 7) , suggesting that either the cross-neutralizing activity may be attributed to an epitope(s) in addition to the CD4 b.s. or the CD4 b.s. induces a complex antibody response involving many discontinuous overlapping epitopes. The latter sugges- VOL. 67, 1993 tion is supported by the observation that three of nine human MAbs mapping to the CD4 b.s. failed to neutralize the 375 S/N mutant ( Table 2 ). The subdivision of this panel of CD4 b.s. MAbs into groups based upon their ability to neutralize 375 S/N suggests that current methods of epitope mapping, recognition of synthetic or site-directed gp120 mutants, and cross-competition assays are insufficiently sensitive to define MAb epitopes completely. These data suggest that single amino acid changes resulting in resistance to one selecting agent may not lead to complete resistance to a polyclonal mixture of antibodies present in a heterologous serum.
